Sutro shells out lat­est up­date on ovar­i­an can­cer treat­ment, plans for piv­otal tri­al

Sutro Bio­phar­ma gave a Phase I up­date on its an­ti­body-drug con­ju­gate for ovar­i­an can­cer Mon­day af­ter­noon, as it plans for a Phase II/III tri­al in the sec­ond quar­ter of 2023.

Tues­day morn­ing, Sutro’s stock {STRO} fell around 11%.

The Bay Area biotech is test­ing its ther­a­py in pa­tients whose tu­mors have fo­late re­cep­tor ɑ, the tar­get of the ADC. Sutro said that in 41 pa­tients who have re­lapsed or pro­gres­sive ovar­i­an can­cer and have pre­vi­ous­ly got­ten plat­inum-based chemother­a­py, 13 had a par­tial re­sponse to its treat­ment known as lu­veltam­ab taze­vibu­lin or STRO-002, good for a 31.7% re­sponse rate. Me­di­an pro­gres­sion free sur­vival was 4.3 months, and the me­di­an du­ra­tion of re­sponse was 5.4 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER